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Faculty of Medical Sciences, University of Kragujevac, Kragujevac, SerbiaA B S T R A C TBackground: Recent studies have shown that ﬁdaxomicin, a novel
antibiotic, can reduce the rate of complications and mortality in
patients with colitis induced by Clostridium difﬁcile. Introduction of
ﬁdaxomicin in clinical practice is limited by its high costs. Objectives:
The purpose of this study was to estimate the cost effectiveness of
using ﬁdaxomicin versus vancomycin in patients with colitis induced
by C. difﬁcile who did not respond to oral metronidazole.Methods: We
constructed a Markov model that was than simulated by Monte-Carlo
simulation using 1000 virtual patients with colitis induced by
C. difﬁcile. The perspective in our model was institutional. The time
horizon was 3 months. Values of transition probabilities and therapy
outcomes were estimated from the available literature, the prices of
health services were obtained from the Republic Institute for Health
Insurance Tariff Book, and the price of ﬁdaxomicin was derived from
data gained from the drug manufacturer. Results: The total costs of
treating one statistical patient for 3 months with ﬁdaxomicin were
higher (48,106.19  118.07 Republic of Serbia dinars [RSD]; 95%ee front matter Copyright & 2014, International S
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ra Markovica 69, 34000 Kragujevac, Serbia.conﬁdence interval 47,988.12–48,224.27) than the total costs of treating
with vancomycin (25,872.85  41.44 RSD; 95% conﬁdence interval
25,831.41–25,914.29). Our results showed that the treatment of infec-
tions induced by C. difﬁcile with ﬁdaxomicin correlated with a lower
rate of mortality and with a smaller number of colectomies. The
incremental cost-effectiveness ratio of ﬁdaxomicin versus vancomy-
cin for colitis induced by C. difﬁcile per saved life was estimated at 2.97
million RSD and for one avoided colectomy at 10.07 million RSD.
Conclusions: Results of our model indicate that ﬁdaxomicin is a cost-
effective therapy compared with vancomycin in patients with colitis
induced by C. difﬁcile if the outcome is life-year saved. However, if the
outcome is the number of avoided colectomies, then ﬁdaxomycin is
not a cost-effective option compared with vancomycin.
Keywords: colitis induced by C. difﬁcile, cost-effectiveness, ﬁdaxomicin.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Clostridium difﬁcile–induced colitis is a serious consequence of
overzealous utilization of broad-spectrum antibiotics, with a
rising rate of mortality [1]. C. difﬁcile is a Gram-positive spore-
forming bacillus, and the NAP1/BI/027 strain of this bacterium is
characterized with an extremely high virulence [2,3]. Diarrhea
and abdominal infections caused by C. difﬁcile correlate with
longer hospitalization, higher costs of treatment, and increased
rate of morbidity and mortality in these patients [4,5].
Antibiotics, especially clindamycin, semi-synthetic penicil-
lins, cephalosporins, and ﬂuoroquinolones, are among the most
frequent causes of colitis and other forms of abdominal infec-
tions caused by C. difﬁcile. Gastrointestinal or other type of
surgery, prolonged hospitalization, compromised immune status
of a patient or any kind of serious comorbidity, advanced age,
parturition, and heart transplantation are well known risk factorsfor C. difﬁcile–induced abdominal infections [6]. The C. difﬁcile
infection is commonly presented as diarrhea with varying
degrees of intensity, caused by C. difﬁcile toxins, especially by
toxin A.4 Because of the intense inﬂammatory potential of toxin
A, and cytotoxic effects of toxin B, the integrity of mucous
membranes is harmed with ulcers and covered with white-gray
ﬁbrin’s layers, which are known as pseudomembranes [7].
The therapeutic approach to C. difﬁcile–induced disease
includes withdrawal of suspicious precipitating antibiotics, main-
tenance of electrolyte balance, and adequate ﬂuid replacement.
This kind of treatment is effective in 25% of the patients [8].
However, for progressive form of C. difﬁcile–induced disease or in
the case of nonresponse to standard therapy, treatment with
speciﬁc antibiotics is required [7]. Oral metronidazole is the ﬁrst-
line antibiotic in less severe forms of C. difﬁcile infections, while
for severe forms and in critically ill patients, oral vancomycin is
the drug of choice [8]. Despite adequate response on oralociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Fig. 1 – Markov model for ﬁdaxomicin treatment versus vancomycin in patients with Clostridium difﬁcile–associated colitis.
CDAC, Clostridium difﬁcile–associated colitis.
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ished by a high rate of recurrence [1].
Fidaxomicin is a novel macrocyclic antibiotic characterized by
low absorption, excellent efﬁcacy, and higher activity in vitro andTable 1 – Transition matrix for a patient treated with ﬁd
B
A Transition
matrix (from
A to B)
Patient
with
CDAC
Clinically cured
patient with
recidivant form
of colitis
Subtota
colectom
with
complet
recovery
Patient with
CDAC
0.07 0.13 0.0071
Clinically cured
patient with
recidivant
form of
colitis
0.07 0.119931 0.0071
Subtotal
colectomy
with
complete
recovery
0 0 1
Subtotal
colectomy
with death
outcome
0 0 0
Death 0 0 0
Fulminant
form of
CDAC
0 0.03325 0.25
Clinically cured
patient
0 0 0
CDAC, Clostridium difﬁcile–associated colitis.in vivo against the NAP1/BI/027 strain of C. difﬁcile than does
vancomycin [9]. The rate of recurrence of C. difﬁcile–induced
disease after treatment with ﬁdaxomicin is 15.4%, which is lower
than after treatment with vancomycin, 25% [1]. The results ofaxomicin.
l
y
e
Subtotal
colectomy
with death
outcome
Death Fulminant
form of
CDAC
Clinically
cured
patient
2 0.003996 0.027 0.018884 0.741522
2 0.003996 0.027 0.018884 0.753069
0 0 0 0
1 0 0 0
0 1 0 0
0.25 0.25 0 0.21657
0 0 0 1
Table 2 – Transition matrix for a patient treated with vancomycin.
B
A Transition
matrix (from
A to B)
Patient
with
CDAC
Clinically cured
patient with
recidivant form
of colitis
Subtotal
colectomy
with
complete
recovery
Subtotal
colectomy
with death
outcome
Death Fulminant
form of
CDAC
Clinically
cured
patient
Patient with
CDAC
0.07 0.220923 0.00712 0.003996 0.027 0.018884 0.652077
Clinically cured
patient with
recidivant
form of
colitis
0.07 0.238639 0.00712 0.003996 0.027 0.018884 0.636361
Subtotal
colectomy
with
complete
recovery
0 0 1 0 0 0 0
Subtotal
colectomy
with death
outcome
0 0 0 1 0 0 0
Death 0 0 0 0 1 0 0
Fulminant
form of
CDAC
0 0.03325 0.25 0.25 0.25 0 0.21657
Clinically cured
patient
0 0 0 0 0 0 1
CDAC, Clostridium difﬁcile–associated colitis.
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effective than vancomycin in the treatment of C. difﬁcile–induced
disease [10,11]. Postantibiotic effect is longer after the treatment
of C. difﬁcile–induced disease with ﬁdaxomicin than with vanco-
mycin (5.5 hours and 1.5 hours, respectively) [12]. In favor
of ﬁdaxomicin are also the lower rate of occurrence of
vancomycin-resistant Enterococcus and candidiasis and lack of
suppressive effects on Bacteroides/Prevotella strains [13]. In a
recent published study, ﬁdaxomicin was recognized as a cost-
effective therapeutic option compared with vancomycin in
patients with C. difﬁcile–induced disease [14]. Finally, ﬁdaxomicin
is more effective in the treatment of recidivate forms of colitis
induced by C. difﬁcile, which is another advantage of ﬁdaxomicin
in comparison with vancomycin [15].
However, a high cost should be paid for the beneﬁts of
ﬁdaxomicin. The total cost per patient for a 10-day treatment with
ﬁdaxomicin in the United States is estimated at $2800 [16]. There
are no published data on the cost-effectiveness of ﬁdaxomicin
versus vancomycin for the treatment of colitis induced by C difﬁcile
in the economic environment of South West Balkan countries. The
aim of this study was to assess the cost-effectiveness of ﬁdaxomicin
and vancomycin for the treatment of C difﬁcile–induced colitis in the
economic environment of Serbia.Methods
We conducted a cost-effectiveness analysis using the Markov
model for patients with colitis induced by C. difﬁcile who did not
respond to oral therapy with metronidazole. The model was
constructed using Microsoft Excel (version 7). Two maintherapeutic strategies, according to the available therapeutic guide-
lines [17] for colitis induced by C. difﬁcile, were compared in our
model: 10-day oral therapy with ﬁdaxomicin (200 mg per 12 hours)
and 10-day oral therapy with vancomycin (125 mg per 6 hours). For
each therapeutic option, virtual patients were in one of the
following health states with possibilities of moving to another
health state at the end of the model cycle: colitis induced by C.
difﬁcile, relapse of colitis induced by C. diifﬁcile, subtotal colectomy
with complete recovery, subtotal colectomy with death outcome,
fulminant form of colitis induced by C. difﬁcile, complete response,
and death (Fig. 1) The states of the model were deﬁned on the basis
of the natural course of the C difﬁcile–associated colitis
[1,10,11,13,15,18].
The perspective in our model was that of the purchaser of the
health care service (Republic Institute for Health Insurance [RIHI],
Serbia). The time horizon was 3 months; there were six cycles,
with the duration of each cycle being 15 days. Discount rate was
not included because of the short length of the time horizon.
Transition probabilities were obtained from available published
clinical studies, which were retrieved from systematic searches
of Medline database using ﬁdaxomicin and Clostridium difﬁcile as
key words [13,15,18]. The main outcomes in our model were the
number of saved lives and the number of avoided subtotal
colectomies. The costs were estimated for every health state in
a model, and because of the institutional perspective of our
study, only direct costs were analyzed: costs of medications,
costs of inpatient services, costs of laboratory services, and costs
of surgical interventions. Service utilization (on which the cost
calculations were made) was estimated using guidelines for the
treatment colitis induced by C. difﬁcile and already published
pharmacoeconomic studies [17,19]. The prices of health services
Table 3 – Number of used health care services per cycle in the model, and total costs per cycle for one patient treated with ﬁdaxomicin (including the
costs of ﬁdaxomicin).
State Utilization
of health
care
services
Enzyme
immunoassay
for detecting
toxin A and
toxin B
(1093.66 RSD)
Fidaxomicin
(10-d
therapy;
200 mg/12 h;
$2800)
Number
of
inpatient
days,
regular
care
(1386.66
RSD/d)
Number
of
inpatient
days,
intensive
care
(3396.8
RSD/d)
White
blood cell
count
(686.4RSD
for 10 d)
Measuring
the serum
level of
lactate
(2319.4
RSD for 10
d)
Measuring
the serum
level of
creatinine
(2319.4
RSD for 10
d)
Subtotal
colectomy
wih
ileostomy
(14 155.14
RSD)
Ileorectal
anastomosis
(18119.84
RSD)
Total
costs
(RSD)
1 Patient with
CDAC
1 1 25.8 0 1 1 1 0 0 263,990.132
2 Clinically
cured
patient
with
recidivant
form of
colitis
1 1 25.8 0 1 1 1 0 0 263,990.132
3 Subtotal
colectomy
with
complete
recovery
1 1 0 24.7 1 1 1 1 1 344,382.74
4 Subtotal
colectomy
with
death
outcome
1 1 0 24.7 1 1 1 1 0 326,262.9
5 Death 0 0 0 0 0 0 0 0 0 0
6 Fulminant
form of
CDAC
1 1 0 14.8 1 1 1 0 0 278,482.208
7 Clinically
cured
patient
0 0 0 0 0 0 0 0 0 0
CDAC, Clostridium difﬁcile–associated colitis; RSD, Republic of Serbia dinars.
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Table 4 – Number of used medical services per cycle in model, and total costs per cycle for one patient treated with vancomycin (including the costs of
vancomycin).
Utilization
of medical
services
Enzyme
immunoassay
for detecting
toxin A and
toxin B
(1093.66 RSD)
Vancomycin
(10-d
therapy;
125 mg/6 h;
5840.0 RSD)
Number
of
inpatient
days,
regular
care
(1386.66
RSD/d)
Number
of
inpatient
days,
intensive
care
(3396.8
RSD/d)
White
blood
cell
count
(686.4
RSD for
10 d)
Measuring
serum
level of
lactate
(2319.4
RSD for 10
d)
Measuring
serum
level of
creatinine
(2319.4
RSD for 10
d)
Subtotal
colectomy
with
ileostomy
(14 155.14
RSD)
Ileorectal
anastomosis
(18119.84
RSD)
Total
costs
(RSD)
Patient with
CDAC
1 1 25.8 0 1 1 1 0 0 48,034.688
Clinically
cured
patient
with
recidivant
form of
colitis
1 1 25.8 0 1 1 1 0 0 48,034.688
Subtotal
colectomy
with
complete
recovery
1 1 0 24.7 1 1 1 1 1 128,427.296
Subtotal
colectomy
with
death
outcome
1 1 0 24.7 1 1 1 1 0 110,307.456
Death 0 0 0 0 0 0 0 0 0 0
Fulminant
form of
CDAC
1 1 0 14.8 1 1 1 0 0 62,526.764
Clinically
cured
patient
1 0 0 0 0 0 0 0 0 0
CDAC, Clostridium difﬁcile–associated colitis; RSD, Republic of Serbia dinars.
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Fig. 2 – Incremental cost-effectiveness ratio (ICER) for ﬁdaxomicin vs. vancomycin in patients with colitis caused by Clostridium
difﬁcile, per lives saved. *Blue line, value of the statistical life in the Republic of Serbia (53 million RSD per life saved).
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ﬁdaxomicin was derived from data gained from a drug manu-
facturer [21–26].
The process of modeling requires the deﬁnition of willingness
to pay, that is, how much a society is willing to pay for one
quality-adjusted life-year gained (QALY) with certain treatment
of a disease. Because we estimated the numbers of lives saved,
we used the value of statistical life as a threshold in our model,
which was estimated at 53,307,040,00 Republic of Serbia dinars
(RSD), according to Weinstein [27] and Perovic ́ and Jankovic ́ [28].
For the other outcome, the number of avoided colectomies, the
threshold was estimated as the value of one colectomy according
to Vaid et al. [29].
To check the robustness of our model, we performed one-way
sensitivity analyses by decreasing the cost of ﬁdaxomicin by 50%.Results
Transition probabilities for each health state for a patient treated
with ﬁdaxomicin are presented in Table 1, and transitionFig. 3 – Incremental cost-effectiveness ratio (ICER) for ﬁdaxomicin
difﬁcile per total colectomy avoided. *Red line, estimated threshoprobabilities for every health state for a patient treated with
vancomycin are presented in Table 2.
Utilization data of health care services and costs for health
states with ﬁdaxomicin and vancomycin are presented in
Tables 3 and 4.
Total costs for the treatment of one statistical patient with
ﬁdaxomicin for 3 months were higher (48,106.19  118.07 RSD;
95% conﬁdence interval [CI] 47,988.12–48,224.27) than for treat-
ment with vancomycin (25,872.85  41.44 RSD; 95% CI 25,831.41–
25,914.29). The rate of the number of patients with colitis induced
with C. difﬁcile who underwent total colectomy was signiﬁcantly
lower in the ﬁdaxomicin group than in the vancomycin group
(0.014  0.00; 95% CI 0.001471–0.01472 vs. 0.016  0.005; 95% CI
0.01691–0.01693, respectively). The mortality rate was higher in
the vancomycin group (0.057  0.00; 95% CI 0.0577–0.0578) than in
the ﬁdaxomicin group (0.050  0.00; 95% CI 0.05025–0.05029). The
differences between these two groups were signiﬁcant in terms of
costs (Т ¼ 142.529; P ¼ 0.000), mortality (Т ¼ 67.101; P ¼ 0.000),
and the number of total colectomies (Т ¼ 67.209; P ¼ 0.000).
The incremental cost-effectiveness ratio for ﬁdaxomicin ver-
sus vancomycin was 2,977,621.51  29,733.10 RSD (95% CIvs. vancomycin in patients with colitis caused by Clostridium
ld per total colectomy avoided.
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101,310.61 RSD (95% CI 10,073,536.36–10,276,757.50) per avoided
colectomy, as shown in Figs. 2 and 3.
To check the robustness of our conclusion, we carried out a
one-way sensitive analysis in which the cost of ﬁdaxomicin was
decreased by 50%. The results indicate that with the lower cost of
ﬁdaxomicin, one life saved with ﬁdaxomicin instead of vanco-
mycin requires an investment of 742,859.86  14,466.33 RSD (95%
CI 728,393.54–757,326.19) and one avoided total colectomy costs
2,538,505.76  49,436.10 RSD (95% CI 2,489,069.66–2,587,941.87).Discussion
Fidaxomicin is a novel therapy for infections caused by C. difﬁcile
[1]. These infections are characterized by high morbidity, an
increased level of complications such as perforation requiring
total colectomy, and a higher mortality rate. Appearance of the
new and more virulent C. difﬁcile strain BI/NAP1/027 correlates
with severe forms of the disease, poor outcomes after standard
therapy with metronidazole, and a high level of recurrence [3].
Fidaxomicin is a recently approved therapeutic option for infec-
tions caused by C. difﬁcile, with a lower rate of recurrence
compared with standard therapy with vancomycin or metroni-
dazole [30]. The use of ﬁdaxomicin, however, is limited by its high
cost ($2800 for 10-day treatment) [16]. Because the patent for
ﬁdaxomicin expires in 2027, one cannot expect lower costs of
ﬁdaxomicin in the near future [31]. The main advantage of
ﬁdaxomicin compared with standard therapy for the treatment
of infections induced by C. difﬁcile is a lower rate of severe
complications and death. Our results show that the treatment
of infections induced by C. difﬁcile with ﬁdaxomicin correlate with
a lower rate of mortality (a difference of 7.6%) and the number of
total colectomies (a difference of 2.2%).
In the Serbian economic environment, pharmacoeconomical
evaluations of ﬁdaxomicin or other new drugs are “blurred,” with
unrealistically low prices of health care services (controlled by
the RIHI) in comparison with other health insurance systems in
the region [32–34].
In the socioeconomic environment of the Republic of Serbia,
the value of statistical life is estimated at 53,307,040.00 RSD
[27,28]. The results of our study indicate that the value of ICER
for ﬁdaxomicin versus vancomycin per life gained is 2.9 million
RSD, which is below the estimated threshold of 53.3 million RSD
(US $628,797.97), and favors ﬁdaxomicin as a cost-effective
therapeutic option for the treatment for colitis induced by C.
difﬁcile compared with vancomycin. However, 10.1 million RSD
that the RIHI should invest to avoid one total colectomy in
patients with colitis induced by C. difﬁcile is much above the
threshold value, which classiﬁes ﬁdaxomicin as not a cost-
effective therapeutic strategy.
Results of Stranges et al. [14] indicate that in the United States,
economic and social environment total costs in patients treated
with ﬁdaxomicin are higher than in patients treated with vanco-
mycin, but ﬁdaxomicin is still a cost-effective therapeutic strat-
egy in mild to moderate infections caused by C. difﬁcile. This is
logical because the health care services that are avoided with
ﬁdaxomicin are very costly in the United States; therefore,
signiﬁcant savings could be made, which partially offset the high
acquisition costs of ﬁdaxomicin. In Serbia and other countries of
South West Balkans, the value of human labor is much lower
than in the United States or in developed countries of Western
Europe, and consequently the costs of health care services are 10
to 30 times lower (e.g., 1 day in a hospital in Serbia costs from €15
to €30, while the cost of 1 day of hospitalization in Germany or
France ranges between €300 and €900). Therefore, decrease in the
length of hospitalization and avoidance of total colectomies withﬁdaxomicin do not translate into sufﬁcient savings in Serbia to
offset the high acquisition costs of ﬁdaxomicin; yet, although not
cost-effective for the avoidance of total colectomies, ﬁdaxomicin
is still cost-effective in Serbia when lives saved is taken as an
outcome. Fidaxomicin would be a cost-effective therapeutic
strategy for the avoidance of total colectomies if the RIHI would
invest about 12 million RSD per colectomy avoided. It shows that
because of its high efﬁcacy, ﬁdaxomicin could be a cost-effective
option even in countries with low national income and cheap
human labor, as is the case within the South West Balkan region.
The sensitivity analyses showed that ﬁdaxomicin would be a
more cost-effective therapeutic option for colitis induced by
C. difﬁcile if the price of ﬁdaxomicin decreases by 50%, but it still
relates only to saved lives as an outcome and not to total
colectomies avoided. Because a further decrease in the acquis-
ition costs of ﬁdaxomicin could be expected only with the
introduction of generic copies of that drug in the market (which
is possible after the year 2027), ﬁdaxomicin will be used on a
small scale in Serbia in the next decade. We could expect a better
pharmacoeconomic proﬁle of ﬁdaxomicin if we judiciously select
our patients. In our model, we did not focus on patients with
severe recidivant form of colitis induced by C. difﬁcile who need
parenteral administration of antibiotics, and that is exactly the
subpopulation of patients in which ﬁdaxomicin is even more
effective than vancomycin and also with a lower rate of recur-
rence [35–40]. Introduction of ﬁdaxomicin in the ofﬁcial national
treatment algorithm for colitis induced by C. difﬁcile could
minimize the rate of complications in selected patients with
more severe forms of the disease and provide signiﬁcant eco-
nomic beneﬁt for health care systems in Serbia and other
countries in the region.
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